Background: Enfuvirtide was shown to be highly effective in treatment-experienced patients. Data on discontinuation of enfuvirtide and switch to new antiretroviral drugs are scarce. We aimed to evaluate the efficacy and the impact of discontinuing and/or switching enfuvirtide on virologic and clinical parameters in clinical practice. Methods: All HIV-infected individuals participating in the Swiss HIV Cohort Study who were treated with enfuvirtide for at least 4 weeks in combination with an optimized background antiretroviral regimen were included in this study. Results: A total of 151 patients were analyzed. The median baseline CD4 cell count was 108 cells/µL (interquartile range [IQR] 50-206) and HIV RNA was 4.7 log 10 copies/mL (IQR 4.1-5.2). Virologic suppression, defi ned as a viral load below 50 copies/mL at 12 months, was achieved by 57.6% of patients. Overall, a median CD4 cell increase of 121 cells/µL (IQR 50-189) from baseline was noted. Up to 50% of patients discontinued enfuvirtide within the fi rst year of treatment, mainly because of the patient's choice. After discontinuation of enfuvirtide, high rates of virologic failure and clinical progression were observed, notably when CD4 cell count at stopping enfuvirtide was below 100 cells/µL and no switch to new potent antiretroviral drugs such as darunavir, maraviroc, or raltegravir was performed. Conclusions: Enfuvirtide provides high virologic and immunologic response in treatment-experienced patients in the setting of clinical practice. Enfuvirtide should not be discontinued but should be replaced by new potent antiretrovirals, particularly in case of severe immunosuppression.
nfuvirtide, the fi rst fusion inhibitor, represents an important advance in the treatment of HIV-infected individuals with virologic failure and limited therapeutic options due to multiple resistances and/or drug toxicity. Enfuvirtide has been shown to provide durable virologic suppression and immunological recovery in randomized clinical trials with triple-class treatment-experienced HIV-infected individuals. [1] [2] [3] [4] [5] A signifi cant delay of time to virological failure in all patients treated with enfuvirtide was demonstrated in the TORO 1 and 2 trials, even if no active drug was included in the antiretroviral background regimen. 6 Moreover, this drug has been used as part of an optimized background therapy with other new agents, such as tipranavir, darunavir, and raltegravir. [7] [8] [9] [10] [11] [12] Nevertheless, the twice-daily subcutaneous administration route and the high frequency of injection site reactions may compromise daily activities and quality of life, leading to drug discontinuation, particularly if potent alternatives become available. 2, 3, 13 In this context, data on long-term outcome of patients discontinuing enfuvirtide, most notably if switched to new antiretroviral drugs, are certainly needed.
Aims of this study were to evaluate the effi cacy of enfuvirtide in heavily pretreated HIV-infected individuals and the impact of discontinuing enfuvirtide and switching to new antiretroviral drugs on virological and clinical parameters in the setting of a large cohort study.
METHODS

Study Design
This study was an analysis of the Swiss HIV Cohort study (SHCS) database, 14 a large prospective cohort study with continuous enrollment of HIV-infected individuals aged 16 years or older. Basic sociodemographic characteristics, data on the clinical course (occurrence of opportunistic infections, cardiovascular diseases, death), co-infection with hepatitis B and C, antiretroviral therapy, and immunologic and virologic parameters are collected at enrollment into the study and every 6 months thereafter on standardized data collection forms. AIDS-defi ning diseases are recorded using the 1993 revised clinical defi nition of AIDS from the Centers for Disease Control and Prevention. 15 The cause of death is reported using the 10th revision of the International Classifi cation of Diseases and Related Health Problems (ICD-10). 16 For the present analysis, we used the SHCS database extract of June 2008.
Study Population
All HIV-infected individuals participating in the SHCS who were treated with enfuvirtide for at least 4 weeks in combination with an optimized background antiretroviral regimen between March 2001 and April 2007 were included in this study.
Defi nitions
Discontinuation of enfuvirtide was defi ned as stopping treatment for at least 30 days or switching to another antiretroviral regimen. The main reason for stopping enfuvirtide was classifi ed according to fi ve categories: patient's wish, physician's decision, virologic failure, toxicity or intolerance, or other reason.
As in the TORO trials, early virologic response to enfuvirtide was shown to be predictive of long-term outcome 17 ; response to treatment was assessed by the proportion of patients achieving virologic suppression, defi ned as an HIV RNA below 50 copies/mL, and by the change in CD4 cell count from baseline to 12 months after starting enfuvirtide.
A clinical event was defi ned as the occurrence of a new AIDS-defi ning disease or HIV-related death during the fi rst year of treatment and at 6-12 months after discontinuation of enfuvirtide. In patients with a previous AIDS diagnosis, we considered only new AIDS-defi ning disorders and excluded recurrences.
Statistical Analysis
Basic sociodemographic characteristics, CD4 cell count, HIV viral load, and antiretroviral therapy were compared using the chi-square test for categorical variables and the Mann-Whitney test for continuous variables. Logistic regression was used to estimate the odds ratios of achieving virologic suppression at 12 months after starting enfuvirtide. Cox regression was used to estimate the hazard ratios of new AIDS-defi ning diseases and HIVrelated deaths within the fi rst year after starting enfuvirtide and at 6-12 months after discontinuation of enfuvirtide, excluding those patients who died within 30 days after discontinuing enfuvirtide (n = 4). Clinical progression was displayed using Kaplan-Meier plots. All patients were censored at 1 year if no clinical event had occurred. All analyses were performed using STATA™ software version 9.2 for Windows (Stata Corp., College Station, Texas, USA).
RESULTS
Study Population
A total of 151 HIV-infected individuals participating in the Swiss HIV Cohort Study who were treated with enfuvirtide for at least 4 weeks were included in this study. Thirty-nine individuals (25.8%) had participated in the TORO 2 trial. Baseline characteristics are shown in Table 1 .
Virologic Suppression and Immunologic Recovery
A total of 57.6% heavily pretreated HIV-infected individuals treated with enfuvirtide in combination
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with an optimized background regimen achieved a viral load below 50 copies/mL at 12 months after starting treatment. The proportion of patients who maintained a HIV RNA below 50 copies/mL on treatment was 61.3% and 64.9% at 24 and 36 months, respectively. In the intention-to-treat analysis, in which discontinuation of enfuvirtide was considered as a failure, a viral load below 50 copies/mL was attained by 39.6%, 37.7%, and 27.2% of patients at 12, 24, and 36 months, respectively. Overall, the median CD4 cell count at 12 months was 254 cells/µL (interquartile range [IQR] 153-349), corresponding to a median increase of 121 cells/µL (IQR 50-189) from baseline.
In the multivariate analysis, a low baseline HIV viremia <5.0 log 10 copies/mL and a backbone regimen containing boosted darunavir or tipranavir were independently associated with higher odds of virologic suppression after adjustment for age, HIV transmission risk, baseline CD4 cell count, HIV RNA, and antiretroviral treatment.
Clinical Progression on Treatment
During a total follow-up period of 126 personyears (py), 13 individuals experienced a new AIDS-defi ning disease and 9 patients died. Of these, two deaths were reported to be HIV-related (non-Hodgkin's lymphoma and pneumonia). Six additional patients who had been censored at the occurrence of a new AIDS-defi ning disease died within the fi rst year after starting enfuvirtide. The rate of clinical progression amounted to 11.7 events (95% CI 7.1-19.4) per 100 py if only AIDS-defi ning diseases and HIV-related deaths were considered and 16.9 events (95% CI 11.1-25.7) per 100 py if deaths from all causes were included. The most frequent AIDS-defi ning diseases were esophageal candidiasis (30.8%) and Pneumocystis jiroveci pneumonia (15.4%), followed by Kaposi's sarcoma, nonHodgkin's lymphoma, primary lymphoma of the brain, and cytomegalovirus retinitis. In the multivariate analysis, after adjustment for age, baseline 
Discontinuation of Enfuvirtide
During a follow-up period of 173 py, 82 patients discontinued enfuvirtide for at least 1 month or switched to another antiretroviral regimen after a median of 345 days (IQR 176-686). Of these, 45 discontinuations occurred during the fi rst year of treatment, corresponding to a discontinuation rate of 32.6 (95% CI 24.1-44.1) per 100 py. The most frequent reasons for stopping enfuvirtide were the patient's choice (49.1%), followed by the physician's decision (15.5%), virologic failure (5.3%), and toxicity (15.1%). After stopping enfuvirtide, 36 out of 82 (43.9%) patients switched to new antiretroviral drugs; of those, 7 received new drugs including darunavir, maraviroc, or raltegravir, and 18 (22%) patients discontinued all antiretrovirals without switch to other regimens. Among all sociodemographic factors investigated, higher education was associated with lower risk of treatment discontinuation (Table 2a) .
At stopping enfuvirtide, 31 out of 82 (37.8%) patients had achieved a viral load below 50 copies/mL, and the median CD4 cell count was 169 cells/µL (IQR 84-332). Among 56 patients with available data at 6 months after stopping enfuvirtide, 35.7% had a viral load below 50 copies/mL at stopping enfuvirtide and 6 months later. The median CD4 cell count was 187 cells/µL (IQR 49-333) at 6 months after stopping enfuvirtide, and the rate of clinical progression was 32.2 (95% CI 20.0-51.8) events per 100 py in the fi rst year after stopping enfuvirtide. Twelve patients experienced a new AIDS-defi ning disease and 9 patients died; of these deaths, 5 were reported to be HIV-related (non-Hodgkin's lymphoma in 2 patients, wasting in 2 patients, and pneumonia in 1 patient). Eight additional patients, who had been censored at the occurrence of an AIDS-defi ning condition, died within the fi rst year after stopping enfuvirtide.
In the multivariate analysis, after adjustment for age, CD4 cell count, virologic suppression at stopping enfuvirtide, and new antiretroviral regimen, the strongest risk factor of clinical progression was severe immunosuppression with a CD4 cell count of less than 100 cells/µL at discontinuation of enfuvirtide (HR 5.1, 95% CI 1.45-18.0, p = .011, compared with CD4 cells ≥200), whereas switch to new antiretroviral drugs such as boosted tipranavir, darunavir, raltegravir, or maraviroc was clearly associated with lower risk of clinical progression (HR 0.07, 95% CI 0.01-0.53, p = .010) (Table 2b,  Figure 1) .
DISCUSSION
This study, involving 151 heavily pretreated HIV-infected individuals who started enfuvirtide in combination with an optimized antiretroviral background regimen, indicates that high virologic and immunologic response rates to treatment may be achieved in the setting of clinical practice. However, up to 50% of patients discontinued enfuvirtide within the fi rst year of treatment, mainly because of the patient's choice. After discontinuation of enfuvirtide, high rates of virologic failure and clinical progression were observed, if CD4 cell count at stopping enfuvirtide was below 100 cells/µL and no switch to new potent antiretroviral drugs such as darunavir, maraviroc, or raltegravir was performed.
In our study, enfuvirtide was associated with signifi cant virologic suppression and led to immunological recovery in HIV-infected individuals with extensive treatment history, in particular to a rapid increase in CD4 cell count above 200 cells/µL. This confi rms fi ndings of randomized clinical trials and small observational studies. 2, 4, 5, 12, 16, 17 Drug potency, resistance, adverse effects, and interactions may infl uence the effi cacy of antiretroviral therapy. In this study, a baseline HIV RNA below 5.0 log 10 copies/mL and an antiretroviral regimen containing new potent antiretroviral drugs like tipranavir and darunavir were independently associated with higher odds of achieving virologic suppression at 12 months. This suggests that individuals with less advanced HIV disease and stronger backbone regimes, refl ecting a lower number of drug resistance mutations, are most likely to benefi t from a treatment with enfuvirtide. These fi ndings are consistent with results of the TORO 1 and 2 trials where four independent predictors of virologic suppression at Week 24 were identifi ed, namely a baseline CD4 cell count above 100 cells/µL, a viral load below 100,000 copies/mL, at least two backbone antiretrovirals to which the HIV virus 
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remains susceptible, and prior exposure to less than 10 antiretroviral drugs.
1,2 Moreover, the addition of enfuvirtide to tipranavir, darunavir, or raltegravir in randomized clinical trials was associated with a greater proportion of patients achieving virologic suppression at 24 weeks, which highlights the importance of combining newer drugs with enfuvirtide if virus is highly resistant to most available drugs. 7, [9] [10] [11] 18 As previously reported in the literature, [19] [20] [21] [22] baseline CD4 cell count was the strongest predictor of clinical progression within the fi rst year after starting enfuvirtide, with a linear increase in the hazard ratios of new AIDS-defi ning diseases and HIV-related deaths with increasing level of immunodefi ciency, in particular if CD4 count was below 50 cells/µL. Several additional factors may contribute to the prognosis of HIV-infected patients after starting enfuvirtide, such as management of drugrelated side effects and interactions, treatment of opportunistic infections, and co-morbidities such as chronic hepatitis B and C.
Discontinuation of Enfuvirtide
Up to 50% of patients discontinued enfuvirtide, mainly within the fi rst year of treatment. The most frequent reason for stopping enfuvirtide was the patient's choice, followed by the physician's decision including virologic failure and switch to new antiretroviral drugs and toxicity. The discontinuation rate of enfurvitide in our study was markedly higher than in the TORO 1 and 2 trials, where only 26.5% of patients stopped enfuvirtide before Week 48; of those, only 4%-14% discontinued because of injection site reactions such as induration, erythema, pain, and discomfort. 3 This difference may presumably be explained by the increasing availability over the past few years of potent alternative antiretroviral drugs with improved tolerability and safety. Selection bias may also have affected our results, since participants of clinical trials are more likely to be highly motivated and adherent to treatment. It is interesting that, in our study population, lower level of schooling was the strongest risk factor of treatment discontinuation within the fi rst year of treatment, suggesting that socioeconomic factors may play an important role in coping with adverse reactions. Consistently, intravenous drug use tended to be associated with higher risk of discontinuing enfuvirtide, which failed statistical signifi cance due to the low number of patients. Self-administration of enfuvirtide through subcutaneous injections requires training and support in order to minimize any potential negative impact on patient lifestyle and adherence to treatment.
After discontinuation of enfuvirtide, high rates of virologic failure and clinical progression were observed. Severe immunosuppression with a CD4 cell count of less than 100 cells/µL at discontinuation of enfuvirtide was the strongest risk factor of clinical progression, whereas patients who were switched to new antiretroviral drugs such as darunavir, maraviroc, and raltegravir were less likely to experience a new AIDS-defi ning disease or to die in the fi rst year after stopping enfuvirtide. These fi ndings demonstrate that enfuvirtide should not be discontinued but replaced by new active drugs, particularly in patients with advanced HIV disease. Recently, the integrase inhibitor raltegravir was shown to be a valuable replacement of enfuvirtide, providing similar effi cacy in heavily pretreated individuals who switched from enfuvirtide to raltegravir with the advantage of easier oral administration and improved tolerability.
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Strengths and Limitations
The strengths of our study were the high number of patients investigated in the setting of clinical practice, and the availability of data on clinical progression after discontinuation of enfuvirtide. There are some limitations to our study. Data on baseline genotypic and phenotypic resistance testing, which is recommended for selecting a background regimen for enfuvirtide, [24] [25] [26] were not available for the present analysis. This may have confounded the association between backbone antiretroviral therapy and virologic suppression, possibly underestimating the potency of newer drugs used as background treatment. Misclassification of the reason for discontinuing enfuvirtide may have occurred, since many factors may play a role in decision making. In particular, patients discontinuing enfuvirtide because of virologic failure may have been coded as "physician's decision." Moreover, no code for treatment simplifi cation exists in the SHCS database as a reason for stopping a specifi c drug, although these individuals have probably been coded as patient's choice or physician's decision. Finally, our results may have been affected by selection bias following the longitudinal design with loss to follow-up and the high number of treatment discontinuations. This may have led to an overestimation of the virologic and immunologic response to enfuvirtide, since patients who better tolerate antiretroviral therapy are more likely to have optimal adherence and thus attain higher virologic suppression. It is also possible that individuals who discontinued enfuvirtide and did not switch to other antiretroviral regimens represent a selection of patients with multidrug resistant virus, poorer compliance, and therefore virologic failure.
CONCLUSIONS
Enfuvirtide in combination with an optimized background antiretroviral therapy provides high virologic response rates and immunologic recovery in treatment-experienced HIV-infected individuals, also in the setting of clinical practice. Nevertheless, a high proportion of patients discontinue enfuvirtide mainly because of the patient's choice and availability of new potent antiretroviral regimes with improved tolerability. After discontinuation of enfuvirtide, high rates of clinical progression are observed if no switch to new potent antiretroviral drugs such as darunavir, maraviroc, or raltegravir is performed.
